^Kamei, K.; Maeda, N.; Nomura, K.; Shibata, M.; Katsuragi-Ogino, R.; Koyama, M.; Nakajima, M.; Inoue, T.; Ohno, T. (2006). „Synthesis, SAR studies, and evaluation of 1,4-benzoxazepine derivatives as selective 5-HT1A receptor agonists with neuroprotective effect: Discovery of Piclozotan.”.Bioorganic & Medicinal Chemistry.14 (6): 1978—1992.PMID16290165.doi:10.1016/j.bmc.2005.10.046.
^Ferro, J.; Dávalos, A. (2006). „Other neuroprotective therapies on trial in acute stroke”.Cerebrovascular diseases (Basel, Switzerland). 21 Suppl 2 (2): 127—130.PMID16651823.doi:10.1159/000091712.
^Mondick, J.; Oo, C.; Patel, D.; Fujitani, T.; Shimizu, K.; Barrett, J. (2009). „Population pharmacokinetics of the selective serotonin 5-HT1A receptor partial agonist piclozotan”.American journal of therapeutics.16 (2): 106—115.PMID19300037.doi:10.1097/MJT.0b013e31816b8c85.}
Y
Podaci na Vikipodacima
